Growth Hormone Deficiency
145
9
10
95
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
28 trials with published results (19%)
Research Maturity
95 completed trials (66% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
10.3%
15 terminated out of 145 trials
86.4%
-0.1% vs benchmark
32%
46 trials in Phase 3/4
29%
28 of 95 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 95 completed trials
Clinical Trials (145)
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)
Effects of GH and Lirglutide on AgRP
Evaluation of (Cardio)Metabolic and Auxological Outcomes of GHD Patients Under rhGH or LAGH With Stratification According to IGF-1 Levels
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
Chromosome 18 Clinical Research Center
Growth and Asymmetric diMethylArginine
Skeletal Muscle Effects of GH in Boys
Biological Age in Children With GH Deficiency Undergoing Hormone Replacement Therapy
The AgRP and GH/IGF-1 Axis in Children
Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy
Body Composition and Adipose Tissue in HIV
Adipose Tissue and Serum Inflammation in GH Deficiency
Development and Validation of a Self-assessment System Based on a Mobile App to Manage Adult Growth Hormone Deficiency
A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)
BELux Children OutcoME During A(@)Dulthood With GHD
Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)